Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($2.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($1.55), Zacks reports. The business had revenue of $17.23 million during the quarter, compared to the consensus estimate of $15.72 million. Kestra Medical Technologies updated its FY 2026 guidance to EPS.
Kestra Medical Technologies Stock Down 3.8%
NASDAQ:KMTS traded down $0.62 during mid-day trading on Friday, reaching $15.84. The stock had a trading volume of 389,680 shares, compared to its average volume of 275,182. Kestra Medical Technologies has a twelve month low of $13.25 and a twelve month high of $26.15. The firm's 50 day moving average price is $19.02.
Institutional Investors Weigh In On Kestra Medical Technologies
Hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth approximately $756,000. Woodline Partners LP acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth approximately $2,510,000. Finally, Millennium Management LLC acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth approximately $11,036,000.
Wall Street Analyst Weigh In
Several brokerages have issued reports on KMTS. Piper Sandler began coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $27.00 price objective on the stock. Wolfe Research initiated coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set an "outperform" rating and a $29.00 price target on the stock. Stifel Nicolaus initiated coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set a "buy" rating and a $28.00 price target on the stock. Wells Fargo & Company lowered their price target on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating on the stock in a report on Thursday. Finally, The Goldman Sachs Group lowered their price target on Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a report on Wednesday, April 16th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $27.33.
View Our Latest Stock Analysis on Kestra Medical Technologies
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Recommended Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access